Safety and efficacy of switching from dulaglutide to tirzepatide across clinically relevant baseline characteristics in participants with T2D: subgroup analysis of SURPASS-SWITCH.

Violante-Ortiz R, Rose L, Sharma P, Gomez Valderas E, Chivukula KK, Kwan AY

BMJ open diabetes research & care30 Mar 2026

PMID41912265PMCIDPMC13052782DOI10.1136/bmjdrc-2025-005711PepBankPUB-41912265

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study10

9 results from studies that gave the peptide. 9 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, switching from dulaglutide to tirzepatide gave significantly greater HbA1c reductions at week 40 in all prespecified baseline subgroups.
In plain wordsIn adults with type 2 diabetes, switching to tirzepatide lowered HbA1c more than staying on dulaglutide in every subgroup studied.
Peptide
Tirzepatide
Outcome
DecreaseHbA1c reduction at week 40 across baseline subgroups
Study
n: not reported in source
Comparator
Dulaglutide 4.5 mg or MTD
Outcome group
Glycemic control · Metabolic and weight
Studied dose
escalation to 15 mg or MTD · 40 weeksAs given in this study (human).
Source sentences
Summary
Reductions in HbA1c and body weight at week 40 were significant and consistently greater with tirzepatide across all prespecified baseline subgroups.
2 context sentences(design, population, supporting numbers)
Summary · context
This study aimed to investigate the efficacy and safety of switching from weekly dulaglutide to weekly tirzepatide in adults with T2D in prespecified baseline subgroups from SURPASS-SWITCH.
Summary · context
Participants were randomly assigned 1:1 to continue with and escalate to dulaglutide 4.5 mg or maximum tolerated dose (MTD) or switch to tirzepatide with escalation to 15 mg or MTD.
Report a problemFND-4191226501
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, switching from dulaglutide to tirzepatide gave significantly greater weight reductions at week 40 in all prespecified baseline subgroups.
In plain wordsIn adults with type 2 diabetes, switching to tirzepatide lowered weight more than staying on dulaglutide in every subgroup studied.
Peptide
Tirzepatide
Outcome
DecreaseBody weight reduction at week 40 across baseline subgroups
Study
n: not reported in source
Comparator
Dulaglutide 4.5 mg or MTD
Outcome group
Body weight · Metabolic and weight
Studied dose
escalation to 15 mg or MTD · 40 weeksAs given in this study (human).
Source sentences
Summary
Reductions in HbA1c and body weight at week 40 were significant and consistently greater with tirzepatide across all prespecified baseline subgroups.
2 context sentences(design, population, supporting numbers)
Summary · context
This study aimed to investigate the efficacy and safety of switching from weekly dulaglutide to weekly tirzepatide in adults with T2D in prespecified baseline subgroups from SURPASS-SWITCH.
Summary · context
Participants were randomly assigned 1:1 to continue with and escalate to dulaglutide 4.5 mg or maximum tolerated dose (MTD) or switch to tirzepatide with escalation to 15 mg or MTD.
Report a problemFND-4191226502
03HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes switched to tirzepatide, HbA1c reduction was greater in the subgroups with higher baseline HbA1c and low baseline BMI.
In plain wordsIn adults with type 2 diabetes switched to tirzepatide, HbA1c fell more in people with higher starting HbA1c and lower BMI.
Peptide
Tirzepatide
Outcome
Not applicableHbA1c reduction by baseline HbA1c and BMI subgroup
Study
n: not reported in source
Comparator
Dulaglutide 4.5 mg or MTD
Outcome group
Glycemic control · Metabolic and weight
Studied dose
escalation to 15 mg or MTD · 40 weeksAs given in this study (human).
Source sentences
Summary
HbA1c reduction was greater in the subgroups with higher baseline HbA1c and low baseline BMI.
2 context sentences(design, population, supporting numbers)
Summary · context
This study aimed to investigate the efficacy and safety of switching from weekly dulaglutide to weekly tirzepatide in adults with T2D in prespecified baseline subgroups from SURPASS-SWITCH.
Summary · context
Participants were randomly assigned 1:1 to continue with and escalate to dulaglutide 4.5 mg or maximum tolerated dose (MTD) or switch to tirzepatide with escalation to 15 mg or MTD.
Report a problemFND-4191226503
04HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes switched to tirzepatide, weight reduction was greater in the non-Hispanic or non-Latino subgroup.
In plain wordsIn adults with type 2 diabetes switched to tirzepatide, weight fell more in the non-Hispanic or non-Latino subgroup.
Peptide
Tirzepatide
Outcome
Not applicableWeight reduction by ethnicity subgroup
Study
n: not reported in source
Comparator
Dulaglutide 4.5 mg or MTD
Outcome group
Body weight · Metabolic and weight
Studied dose
escalation to 15 mg or MTD · 40 weeksAs given in this study (human).
Source sentences
Summary
Weight reduction was greater for participants in the non-Hispanic or non-Latino subgroup.
2 context sentences(design, population, supporting numbers)
Summary · context
This study aimed to investigate the efficacy and safety of switching from weekly dulaglutide to weekly tirzepatide in adults with T2D in prespecified baseline subgroups from SURPASS-SWITCH.
Summary · context
Participants were randomly assigned 1:1 to continue with and escalate to dulaglutide 4.5 mg or maximum tolerated dose (MTD) or switch to tirzepatide with escalation to 15 mg or MTD.
Report a problemFND-4191226504
05HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes switched from dulaglutide to tirzepatide, the safety profile was similar across baseline subgroups.
In plain wordsIn adults with type 2 diabetes switched to tirzepatide, side effects were similar across the subgroups studied.
Peptide
Tirzepatide
Outcome
Not applicableSafety profile across subgroups
Study
n: not reported in source
Comparator
Dulaglutide 4.5 mg or MTD
Outcome group
Adverse events · Whole body
Studied dose
escalation to 15 mg or MTD · 40 weeksAs given in this study (human).
Source sentences
Summary
The safety profile was similar across subgroups.
2 context sentences(design, population, supporting numbers)
Summary · context
This study aimed to investigate the efficacy and safety of switching from weekly dulaglutide to weekly tirzepatide in adults with T2D in prespecified baseline subgroups from SURPASS-SWITCH.
Summary · context
Participants were randomly assigned 1:1 to continue with and escalate to dulaglutide 4.5 mg or maximum tolerated dose (MTD) or switch to tirzepatide with escalation to 15 mg or MTD.
Report a problemFND-4191226505
06HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes switched from dulaglutide to tirzepatide, nausea was usually one of the most frequently reported treatment-emergent adverse events in each subgroup.
In plain wordsIn adults with type 2 diabetes switched to tirzepatide, nausea was one of the most common side effects in each subgroup.
Peptide
Tirzepatide
Outcome
Not applicableNausea
Study
n: not reported in source
Comparator
Dulaglutide 4.5 mg or MTD
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
escalation to 15 mg or MTD · 40 weeksAs given in this study (human).
Source sentences
Summary
Nausea and diarrhea were usually the most frequently reported treatment-emergent adverse events in each subgroup.
2 context sentences(design, population, supporting numbers)
Summary · context
This study aimed to investigate the efficacy and safety of switching from weekly dulaglutide to weekly tirzepatide in adults with T2D in prespecified baseline subgroups from SURPASS-SWITCH.
Summary · context
Participants were randomly assigned 1:1 to continue with and escalate to dulaglutide 4.5 mg or maximum tolerated dose (MTD) or switch to tirzepatide with escalation to 15 mg or MTD.
Report a problemFND-4191226506
07HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes switched from dulaglutide to tirzepatide, diarrhea was usually one of the most frequently reported treatment-emergent adverse events in each subgroup.
In plain wordsIn adults with type 2 diabetes switched to tirzepatide, diarrhea was one of the most common side effects in each subgroup.
Peptide
Tirzepatide
Outcome
Not applicableDiarrhea
Study
n: not reported in source
Comparator
Dulaglutide 4.5 mg or MTD
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
escalation to 15 mg or MTD · 40 weeksAs given in this study (human).
Source sentences
Summary
Nausea and diarrhea were usually the most frequently reported treatment-emergent adverse events in each subgroup.
2 context sentences(design, population, supporting numbers)
Summary · context
This study aimed to investigate the efficacy and safety of switching from weekly dulaglutide to weekly tirzepatide in adults with T2D in prespecified baseline subgroups from SURPASS-SWITCH.
Summary · context
Participants were randomly assigned 1:1 to continue with and escalate to dulaglutide 4.5 mg or maximum tolerated dose (MTD) or switch to tirzepatide with escalation to 15 mg or MTD.
Report a problemFND-4191226507
08HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, continuing dulaglutide produced less HbA1c reduction than switching to tirzepatide across all prespecified baseline subgroups.
In plain wordsIn adults with diabetes, continuing dulaglutide lowered blood sugar less than switching to tirzepatide across the tested subgroups.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c reduction across baseline subgroups
Study
n: not reported in source
Comparator
Switch to tirzepatide up to 15 mg or maximum tolerated dose
Outcome group
Glycemic control · Metabolic and weight
Studied dose
4.5 mg or maximum tolerated dose · 40 weeksAs given in this study (human).
Source sentences
Summary
Reductions in HbA1c and body weight at week 40 were significant and consistently greater with tirzepatide across all prespecified baseline subgroups.
2 context sentences(design, population, supporting numbers)
Summary · context
This phase IV, randomized, open-label, active-controlled, parallel-group, multicenter, multinational trial included adults
Summary · context
Participants were randomly assigned 1:1 to continue with and escalate to dulaglutide 4.5 mg or maximum tolerated dose (MTD) or switch to tirzepatide with escalation to 15 mg or MTD.
Report a problemFND-4191226508
09HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, continuing dulaglutide produced less weight reduction than switching to tirzepatide across all prespecified baseline subgroups.
In plain wordsIn adults with diabetes, continuing dulaglutide reduced weight less than switching to tirzepatide across the tested subgroups.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseBody weight reduction across baseline subgroups
Study
n: not reported in source
Comparator
Switch to tirzepatide up to 15 mg or maximum tolerated dose
Outcome group
Body weight · Metabolic and weight
Studied dose
4.5 mg or maximum tolerated dose · 40 weeksAs given in this study (human).
Source sentences
Summary
Reductions in HbA1c and body weight at week 40 were significant and consistently greater with tirzepatide across all prespecified baseline subgroups.
2 context sentences(design, population, supporting numbers)
Summary · context
This phase IV, randomized, open-label, active-controlled, parallel-group, multicenter, multinational trial included adults
Summary · context
Participants were randomly assigned 1:1 to continue with and escalate to dulaglutide 4.5 mg or maximum tolerated dose (MTD) or switch to tirzepatide with escalation to 15 mg or MTD.
Report a problemFND-4191226509

Studies that did not test the peptide alone1

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

10HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome
In adults with diabetes continuing dulaglutide or switching to tirzepatide, safety profiles were similar across baseline subgroups.
In plain wordsIn adults with diabetes receiving either trial treatment, safety was similar across baseline subgroups.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeSafety across baseline subgroups
Study
n: not reported in source
Comparator
Other baseline subgroups
Outcome group
Adverse events · Whole body
Source sentences
Summary
The safety profile was similar across subgroups.
2 context sentences(design, population, supporting numbers)
Summary · context
This phase IV, randomized, open-label, active-controlled, parallel-group, multicenter, multinational trial included adults
Summary · context
Participants were randomly assigned 1:1 to continue with and escalate to dulaglutide 4.5 mg or maximum tolerated dose (MTD) or switch to tirzepatide with escalation to 15 mg or MTD.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4191226510

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4Results postedNCT05564039

A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)

Eli Lilly and Companyn = 28230 Nov 2022 to 12 Aug 2024

Type 2 Diabetes

Trial page ClinicalTrials.govUpdated 3 Aug 2025

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 4 to 8Current
28 Oct 2026, 02:03 UTC
The same notice was added 5 times, first on 22 Oct 2026, 02:26 UTC. The status did not change between them.
Study results updated
Version 3
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 2
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:07 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.